NBE Therapeutics
↗Basel, Switzerland
NBE Therapeutics is a Swiss-based biotechnology company founded in 2012 and headquartered in Basel, Switzerland. The company specializes in developing next-generation antibody-drug conjugate (ADC) therapies targeting solid tumors, with a focus on improving outcomes for cancer patients. NBE developed proprietary platforms covering all aspects of ADC development: Transpo-mAb Display™ for antibody discovery, SMAC-Technology™ for site-specific payload conjugation, and a novel ultrapotent anthracycline-based toxin platform. In December 2020, NBE Therapeutics was acquired by Boehringer Ingelheim for approximately €1.18 billion (approximately $1.5 billion), representing a significant validation of its ADC technology platform and pipeline. As of 2025, NBE operates as a wholly owned subsidiary of Boehringer Ingelheim, focusing on advancing its ADC portfolio for oncology indications.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2012
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Pre-IPO
Total Raised:$78.5M
Investors:Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings, PPF Group, Swiss Federation Commission for Innovation and Technology, Venture Kick, Swiss and German private investors
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Antibody-Drug Conjugate (ADC), mAb, Anthracycline-based payloads
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Boehringer Ingelheim
Acquired By:Boehringer Ingelheim (2020-12-01)
Key Partnerships:Boehringer Ingelheim: Parent company following acquisition in December 2020, Exelixis: Exclusive collaboration and license option agreement for discovery and development of novel ADCs against multiple targets, SOTIO: Collaboration for discovery, non-clinical development and manufacturing of novel ADCs; SOTIO handles clinical development, registration and commercialization, WuXi Biologics: Comprehensive ADC development and manufacturing partnership for NBE-002 and other candidates
COMPETITION
Position:Challenger
Competitors:Merck (VelosBio partnership - ROR1-directed ADC), Seagen, Immunomedics, Astellas Pharma, Genmab, Jazz Pharmaceuticals, C4 Therapeutics, Regeneron Pharmaceuticals +3 more
LEADERSHIP
Key Executives:
Ulf Grawunder - Founder and CEO
Bertrand Damour - Chief Executive Officer (at time of Boehringer acquisition announcement)
Jim O'Leary - Key Executive
Wouter Verhoeven - Key Executive
Scientific Founders:Ulf Grawunder
Board Members:Detlev Mennerich (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NBE Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.